Literature DB >> 12429142

A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol. Development of a monoclonal antibody to 18-oxocortisol.

Stefania Morra di Cella1, Franco Veglio, Paolo Mulatero, Valerie Christensen, Keli Aycock, Zheng Zhu, Elise P Gomez-Sanchez, Celso E Gomez-Sanchez.   

Abstract

Patients with primary aldosteronism and with glucocorticoid-suppressible aldosteronism excrete in the urine excessive amounts of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol. The measurement of these steroids aids in the differential diagnosis of various adrenal disorders. We have produced mouse monoclonal antibodies against 18-oxocortisol and polyclonal antibodies against 18-hydroxycortisol and describe a time-resolved fluoroimmunoassay (TR-FIA) technique for the measurement of these steroids in the urine. We have also compared this assay with an ELISA technique for these compounds. We also describe the preparation of in-house Eu(III)-labeled avidin and an enhancement solution and compared to a commercially available Eu(III)-labeled streptavidin and enhancement solutions. The monoclonal antibodies against 18-oxocortisol are sensitive and have a high level of specificity. The TR-FIA technique using in-house prepared reagents or commercial ones were indistinguishable from each other, but at a significant saving. The TR-FIA technique was more sensitive and had a greater precision than the ELISA technique for both steroids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429142     DOI: 10.1016/s0960-0760(02)00142-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.

Authors:  Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

2.  18-Oxocortisol Synthesis in Aldosterone-Producing Adrenocortical Adenoma and Significance of KCNJ5 Mutation Status.

Authors:  Yuta Tezuka; Yuto Yamazaki; Masaaki Kitada; Ryo Morimoto; Masataka Kudo; Kazumasa Seiji; Kei Takase; Yoshihide Kawasaki; Koji Mitsuzuka; Akihiro Ito; Jun Nishikawa; Noriko Asai; Yasuhiro Nakamura; Celso E Gomez-Sanchez; Sadayoshi Ito; Mari Dezawa; Hironobu Sasano; Fumitoshi Satoh
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

3.  Development of monoclonal antibodies against human CYP11B1 and CYP11B2.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Carolina Velarde-Miranda; Maria W Plonczynski; C Richard Parker; William Rainey; Fumitoshi Satoh; Takashi Maekawa; Yasuhiro Nakamura; Hironobu Sasano; Elise P Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2013-12-08       Impact factor: 4.102

4.  Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line.

Authors:  Kenji Oki; Phillip G Kopf; William B Campbell; Milay Luis Lam; Takeshi Yamazaki; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-12-07       Impact factor: 4.736

Review 5.  DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Authors:  Jacques W M Lenders; Tracy Ann Williams; Martin Reincke; Celso E Gomez-Sanchez
Journal:  Eur J Endocrinol       Date:  2017-09-13       Impact factor: 6.664

6.  A dilute-and-shoot liquid chromatography-tandem mass spectrometry method for urinary 18-hydroxycortisol quantification and its application in establishing reference intervals.

Authors:  Beibei Zhao; Jin Bian; Menghua Rao; Xuhui She; Ying Lou; Jun Cai; Wenjun Ma
Journal:  J Clin Lab Anal       Date:  2022-07-02       Impact factor: 3.124

Review 7.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.